Home/Enliven Therapeutics/Galya Blachman
GB

Galya Blachman

Chief Legal Officer and Head of Business Development

Enliven Therapeutics

Therapeutic Areas

Enliven Therapeutics Pipeline

DrugIndicationPhase
ELVN-001Chronic Myeloid Leukemia (CML)Phase 1b